Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a comprehensive update on the rapidly evolving landscape of incretin-based therapies, focusing on newly published and top-line clinical trial data across oral GLP-1 receptor agonists and emerging triple agonists.

Key Episode Timestamps
00:00:01 Intro
00:00:22 Orforglipron in the ACHIEVE-3 trial
00:03:30 Side effects from orforglipron
00:10:28 Retatrutide in the TRIUMPH-4 trial
00:18:26 Topline data on Novo Nordisk's UBT251
00:21:47 Price cuts on Ozempic, Rybelsus, and Wegovy in 2027
00:26:26 Outro